anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
BACKGROUND: This study evaluated the relationship between Joint Commission accreditation and health care-associated infections (HAIs) in long-term care hospitals (LTCHs).
METHODS: This observational study used Centers for Medicare & Medicaid Services (CMS) LTCH data for the period 2017 to June 2021. The standardized infection ratio (SIR) of three measures used by the Centers for Disease Control and Prevention's National Healthcare Safety Network were used as dependent variables in a random coefficient Poisson regression model (adjusting for CMS region, owner type, and bed size quartile): catheter-associated urinary tract infections (CAUTIs), Clostridioides difficile infections (CDIs), and central line-associated bloodstream infections (CLABSIs) for the periods 2017 to 2019 and July 1, 2020, to June 30, 2021. Data from January 1 to June 30, 2020, were excluded due to the COVID-19 pandemic.
RESULTS: The data set included 244 (73.3%) Joint Commission-accredited and 89 (26.7%) non-Joint Commission-accredited LTCHs. Compared to non-Joint Commission-accredited LTCHs, accredited LTCHs had significantly better (lower) SIRs for CLABSI and CAUTI measures, although no differences were observed for CDI SIRs. There were no significant differences in year trends for any of the HAI measures. For each year of the study period, a greater proportion of Joint Commission-accredited LTCHs performed significantly better than the national benchmark for all three measures (p = 0.04 for CAUTI, p = 0.02 for CDI, p = 0.01 for CLABSI).
CONCLUSION: Although this study was not designed to establish causality, positive associations were observed between Joint Commission accreditation and CLABSI and CAUTI measures, and Joint Commission-accredited LTCHs attained more consistent high performance over the four-year study period for all three measures. Influencing factors may include the focus of Joint Commission standards on infection control and prevention (ICP), including the hierarchical approach to selecting ICP-related standards as inputs into LTCH policy.
FIELD: virology. SUBSTANCE: present invention describes new biologically active compounds, more particularly 5-H- phosphonate 3-azido-3- desoxytimidine or general formula given in the specification. New compounds are capable of specifically inhibiting human deficiency virus production. This makes it possible to use them for medical purposes for treating AIDS. Said compounds are prepared by neutralization of 5-H-phosphonate 3-azido-3- desoxytimidine with hydroxides of corresponding metals in water to adjust pH to 7-7.2. The resulting soluble salts are evaporated to small volumes. Spontaneous crystallization then occurs and the whole is kept at 4 C for 5-6 hours till crystallization is completed. Precipitants are filtered off, washed with small amounts of water cooled to 4 C and dried. Yield of the desired substances is 95-98%. New compounds inhibit multiplication of VICH-1 and VICH-2 in human lymphocyte cultures H9, MT-4 and PBL and are low or nongygroscopic and thus zacilitate preparation of drugs based thereon. EFFECT: improved properties of the title compounds. 3 tbl
The invention belongs to the health care products field, and particularly relates to compatibility Cordyceps sinensis tablets by stratification molding and a preparation method. The Compatibility Cordyceps sinensis tablets by stratification molding comprises the following 20-30% of Cordyceps sinensis submicron powder, 2-6% of saffron crocus submicron powder and 64-78% of Chinese wolfberry polysaccharide powder. One layer is the Cordyceps sinensis submicron powder, and the other layer is the saffron crocus submicron powder and the Chinese wolfberry polysaccharide powder. The preparation method comprises the following steps: respectively drying the Cordyceps sinensis and saffron crocus to moisture less than or equal to 8%, respectively performing ultramicro crushing to less than or equal to 2000 meshes for standby; then weighting the raw materials according to composition proportion, using a dry method on the Cordyceps sinensis submicron powder for standby; uniformly mixing the saffron crocus submicron powder and the Chinese wolfberry polysaccharide powder, using the dry method for granulation for standby; respectively adding prepared two types of granules in two different hoppers of a layered tablet press, and opening the machine for tabletting to obtain the product. The compatibility Cordyceps sinensis tablets have the efficacy of good immunoloregulation, inhibiting tumor, promoting blood circulation to remove blood stasis and delaying aging. The health care products prepared by the method has the advantages of good curative effect, the cost is low, the process flow is simple, and the operation is simple.
Historical studies have shown that induction chemotherapy can provide an opportunity to preserve the larynx in approximately 60-70% of patients with locally advanced laryngeal/hypopharynx carcinoma. Recently, phase I-II clinical studies have shown that induction of PD-1 inhibitors has a good pathological response in locally advanced head and neck cancer, with or without combined chemotherapy. However,the primary lesion and lymph nodes respond asynchronously or even in the opposite way to immune induction therapy. The primary lesion is more likely to achieve CR/PR, while the lymph nodes are more likely to show PR/SD or even PD. Therefore, the surgical or radiotherapy plan should be implemented according to the specific response of the primary lesion and metastatic lymph nodes to induction therapy. This study aimed to determine whether the combination of induction chemotherapy with a PD-1 inhibitor (Tislelizumab) followed by chemoradiotherapy or adaptive surgery can improve the rate of laryngeal preservation in patients with resectable laryngeal/hypopharynx cancer.
PROBLEM TO BE SOLVED: To provide a sunscreen composition, which is excellent in water resistance, gentle to the skin, and stable to ultraviolet rays.SOLUTION: According to the present invention, there is provided a sunscreen composition comprising two or more oil-soluble ultraviolet absorbers and composite silicone particles having an average particle size of 10 μm or less. The sunscreen composition does not contain a metal oxide. In the sunscreen composition, the oil-soluble ultraviolet absorber is at least two selected from ethylhexyl methoxycinnamate, octocrylene, hexyl diethylaminohydroxybenzoylbenzoate, and polysilicone-15. In the sunscreen composition, the silicone particles are composite silicone particles in which spherical silicone rubber is coated with a silicone resin. In the sunscreen composition, the content of the oil-soluble ultraviolet absorber is 10% by weight or more in total. The sunscreen composition has the form of a water-in-oil (W/O) emulsion.SELECTED DRAWING: None
The invention discloses a memantine paroxetine cocrystal salt and its preparation method, pharmaceutical composition and application thereof. The cocrystal salt of the invention is memantine paroxetine sulfate hydrate. Its mechanism of action is 5-HT inhibitor and NMDA receptor antagonist. It is a multi-target drug. The preliminary pharmacokinetic experiments showed that the main pharmacokinetic parameters of cocrystal salt and memantine, such as t<sub>1/2</sub>, T<sub>max</sub>, C<sub>max</sub> and AUC<sub>(0-∞)</sub>, were significantly different. The results also showed that cocrystal salt could improve drug absorption, blood drug concentration, bioavailability and curative effect. This provides a material basis for reducing dosage and adverse drug reactions. In addition to that the cocrystal salt of this invention can be used as a multi-target drug, it can also combine with other drugs of different action mechanisms to form compound preparations or be used in combination, so as to obtain unexpected clinical efficacy.
Participants randomly assigned to the Treatment-as Usual (TAU) Waitlist Control group will also receive the UPLIFT intervention. However, TAU Waitlist Control participants will begin the Intervention 8 weeks after completing the Baseline Assessment. During the initial 8 weeks, participants in this group will continue whatever treatment they are currently undergoing to prevent or treat mild depressive symptoms. Participants can chose to participate in the Web- or phone-delivery of UPLIFT.
Computational models of tumor growth are valuable for simulating the dynamics of cancer progression and treatment responses. In particular, agent-based models (ABMs) tracking individual agents and their interactions are useful for their flexibility and ability to model complex behaviors. However, ABMs have often been confined to small domains or, when scaled up, have neglected crucial aspects like vasculature. Additionally, the integration into tumor ABMs of precise radiation dose calculations using gold-standard Monte Carlo (MC) methods, crucial in contemporary radiotherapy, has been lacking. Here, we introduce AMBER, an Agent-based fraMework for radioBiological Effects in Radiotherapy that computationally models tumor growth and radiation responses. AMBER is based on a voxelized geometry, enabling realistic simulations at relevant pre-clinical scales by tracking temporally discrete states stepwise. Its hybrid approach, combining traditional ABM techniques with continuous spatiotemporal fields of key microenvironmental factors such as oxygen and vascular endothelial growth factor, facilitates the generation of realistic tortuous vascular trees. Moreover, AMBER is integrated with TOPAS, an MC-based particle transport algorithm that simulates heterogeneous radiation doses. The impact of radiation on tumor dynamics considers the microenvironmental factors that alter radiosensitivity, such as oxygen availability, providing a full coupling between the biological and physical aspects. Our results show that simulations with AMBER yield accurate tumor evolution and radiation treatment outcomes, consistent with established volumetric growth laws and radiobiological understanding. Thus, AMBER emerges as a promising tool for replicating essential features of tumor growth and radiation response, offering a modular design for future expansions to incorporate specific biological traits.
A single 10 mg dose of LY2584702 TF during the first intervention period, followed by a single dose of 50 mg RF in the second intervention period, followed by a single dose of 50 mg TF in the third intervention period, followed by either an open-label single dose of 50 mg TF after a high fat breakfast (Period 4a) OR placebo or escalated dose of TF in the fasted state (Period 4b). There will be a washout period of at least 3 days between periods.
BACKGROUND: Systemic inflammation due to cardiogenic shock is associated with vasoplegia leading to organ hypoperfusion, right heart failure, and poor clinical outcome. Extracorporeal cytokine hemoadsorption emerged to attenuate excessive levels of inflammatory cytokines, potentially improving patient outcomes. Nevertheless, its prognostic impact during high-risk left ventricular assist device (LVAD) implantation remains unknown.
METHODS: In total, 40 consecutive patients with advanced heart failure underwent continuous-flow LVAD implantation at our institution between 2018 and 2020. Out of 25 high-risk patients in cardiogenic shock (Interagency Registry for Mechanically Assisted Circulatory Support profile 1 and 2), 9 patients (CytoSorb group) underwent LVAD implantation with and 16 patients (control group) without simultaneous cytokine hemoadsorption during cardiopulmonary bypass. Besides preoperative patient characteristics, postoperative lactate clearance, vasopressor administration and mean arterial pressure, perioperative complication, and 30-day mortality rates were retrospectively analyzed.
RESULTS: Apart from an increased rate of reoperations within the CytoSorb group, baseline characteristics including the severity of ventricular dysfunction and consecutive signs of end-organ failure were similar in both groups. Preoperative short-term mechanical circulatory support bridging was comparable (66.7 vs. 75%; p = 0.66) prior to LVAD implantation. Procedural characteristics including intraoperative volume management and postoperative vasopressor administration were similar in both groups. There was no difference regarding postoperative lactate clearance, although postoperative mean arterial pressure was significantly higher in the control group (71.3 vs. 57.4 mm Hg; p < 0.01). Furthermore, the 30-day mortality rate was significantly higher in the CytoSorb group (33.3 vs. 0.0%; p = 0.01).
CONCLUSION: Extracorporeal cytokine hemoadsorption during high-risk LVAD implantation was not associated with a decrease of postoperative vasopressor support, improved hemodynamics, or an accelerated lactate clearance.
The invention provides an Adefovir drug cocrystal with para-aminobenzoic acid as a cocrystal former and a preparation method thereof, belonging to the technical field of drug cocrystals. The Adefovir drug cocrystal is characterized in that the space group of the drug cocrystal is a monoclinic system; one Adefovir molecule, two para-aminobenzoic acid molecules and one water molecule are respectively bonded together via hydrogen bonds to form a basic structural unit of the Adefovir-para-aminobenzoic acid drug cocrystal. The solvent selected in the drug cocrystal preparation process is water. A solution cocrystallization method is adopted. As Adefovir is slightly soluble in cold water and is freely soluble in hot water, the crystal is formed by cooling Adefovir after Adefovir is heated, stirred and dissolved and then is put in an oven and is insulated for a period of time. The prepared drug cocrystal inherits the characteristics of traditional active pharmaceutical ingredients in treating hepatitis B, and the solubility, stability and bioavailability of the drug cocrystal are obviously improved.
The invention discloses an external-use complex liquid for adjusting sleep. The external-use complex liquid comprises leaching liquid and medical material leaching object dissolved in the leaching liquid, wherein the medical material leaching object is obtained by the mode that medical materials are soaked in the leaching liquid, and the medical materials comprise, golden hop and folium eucalypti, wherein the weight ratio of the golden hop to the folium eucalypti is 0.01-2:0.01-5. The leaching liquid comprises ethyl alcohol, glycerinum and water, wherein the weight ratio of the ethyl alcohol to the glycerinum to the water is 20-75:1-10:10-78According to the external-use complex liquid, sleep can be effectively promoted, good health is ensured, and the good spiritual outlook is kept. The invention further discloses a preparation method of the external-use complex liquid for adjusting the sleep. The method comprises the following steps: weighing and taking the medical materials and components of a leaching liquid formula, smashing the medical materials, soaking the medical materials in the leaching liquid, filtering, collecting the filtrate, and obtaining the external-use complex liquid. The method is easy to operate and control, low in cost and suitable for industrial production.
Functional independence of the transversus abdominis (TrA) from other trunk muscles for postural control is still unclear. This study aimed to clarify the specific function of the TrA to control standing posture by vibratory stimulation of the triceps surae. Fifteen men participated in this study. Muscle activity of the TrA, internal oblique, lumbar multifidus, gluteus maximus, rectus femoris, biceps femoris, gastrocnemius, and tibialis anterior was measured using fine-wire and surface electrodes. Participants were asked to maintain a quiet standing posture with and without vibration of the triceps surae, which induced a kinesthetic illusion and the concomitant backward sway of the body. The muscle activity of each muscle for 10 s was extracted with and without vibration. The muscle activity levels were compared between the conditions by a paired t-test or Wilcoxon signed-rank test. The activity of the TrA and rectus femoris was increased, whereas the internal oblique showed no change as a result of the induced kinesthetic illusion. In addition, the activity of the multifidus and biceps femoris was decreased. The TrA and rectus femoris could contribute to control the backward sway of the body. Furthermore, the TrA may have functional independence from the internal oblique during standing postural control. These results warrant further study in patients with low back pain.
PROBLEM TO BE SOLVED: To obtain a medicinal composition for liver protection which contains lithospermate B obtained from Tannzinn (Salviae miltiorrhizae radix) having liver-protecting action. SOLUTION: This medicinal composition contains lithospermate B of the formula (M<++> is Mg<++> , Ca<++> or the like) as an active ingredient. The lithospermate B is obtained by extracting Tannzinn (root of Salviae miltiorrhiza Bunge) self-growing in mountains and fields of People's Republic of China with water or a polar solvent such as methanol under neutral conditions, concentrating. separating and purifying the extract. A pharmaceutically permissible substrate and an excipient are suitably formulated thereto to prepare preferably powder, syrup, capsules, granules, emulsion, suspension, drops and administered. The daily dose is 10-10,000mg/adult calculated as lithospermate B.
The Wiidookaage'win Facebook Group is an online, asynchronous group intervention that will run for 3-months with approximately 30 days of content developed. It is private and hidden, meaning only those in the study will be able to see or find the group. It will be moderated by two women from the study team (one AIAN and one biracial). A back-up moderator will also have access to the group. Participants will be able to comment, react, view, and post in the intervention group, and are encouraged to interact with one another.
Capmatinib tablets orally on a continuous dosing BID per 28 day cycle. Everolimus dispersible tablets orally QD on a continuous dosing per 28 day cycle.
Abstract A process for recovering IFN-.beta. from trans-formed bacteria comprising:  disrupting the cell mem-branes of the bacteria  solubilizing the IFN-.beta. from the disruptate into an aqueous medium with a solubili-zing agent such as sodium dodecyl sulfate, extracting the IFN-.beta. from the aqueous medium with 2-butanol, 2-methyl-butanol, or mixtures thereof under conditions that maintain phase separation between the aqueous medium and the extractant; and isolating the IFN-.beta. from the extractant such as by precipitating the IFN-.beta. from an aqueous buffer mixture of the extractant by lowering the pH thereof.
Participants will have a fasted baseline blood sample taken upon arrival to the lab. Then they will take part in a high-intensity exercise protocol, consisting of high-intensity interval cycling, resistance exercise, and plyometrics. Following exercise, participants will return to the lab for a 5min post-exercise blood sample, and then consume \~500ml water. An additional blood sample will be taken at 1h post-exercise, followed by an additional \~500ml water. Blood samples will also be taken at 4h and 24h post-exercise. Participants will also rate their muscle soreness and perform a jump height test at pre-exercise, 5min post-exercise, 4h and 24h post-exercise.
<P>PROBLEM TO BE SOLVED: To provide an antioxidizing compound obtained by subjecting an olive leaf extract to bioconversion with a yeast, to provide an extract containing the compound, to provide a cosmetic additive, a food additive, a cosmetic and a food comprising the extract and to provide a method for producing the compound.  <P>SOLUTION: The novel compound comprises a specific pyran ring. The bread yeast-treated olive extract comprises the compound. Furthermore, the compound is useful as an antioxidizing composition and can be used as the food additive or the cosmetic additive. The compound can be produced by a conversion reaction of an olive extract with the bread yeast.  <P>COPYRIGHT: (C)2008,JPO&INPIT
Women randomized to this study arm will receive intravenous ascorbic acid (50g in 500 ml sterile water) prior to their odd-numbered chemotherapy cycles. During the even-numbered chemotherapy cycles, these subjects will receive intravenous normal saline (0.9%).
This invention relates to a topical gel matrix that can be used alone or combination with a medication entrapped therein. The gel matrix is slowly dispersible in water so that it resists water degradation or disintegration for a substantial amount of time. The contact time with the skin, mucus or mucosa of a treated subject is long enough to allow slow diffusion of a medication entrapped therein. When used alone, the gel matrix provides a physical barrier against the penetration of a pathogen or environmental constituents into the wound, or conversely, contamination from the wound to the environment. It further eliminates or reduces the sensation of burn or irritation when applied on a scratch, injured or wounded skin or mucosa. The get may have the following generic composition: oil, water or aqueous solution; solvents, surfactants and/or detergents; and a polymer which is a consistence modifier capable of thickening and to resist degradation in a water environment.      Aculyn 44TM is a preferred example of such a polymer. The matrix may comprise or not a biologically active ingredient. The ingredient is for a systemic or topical indication. Amongst preferred medications are anaesthetic, anti-histaminic, anti-inflammatory, anti-oxidant, anti-UVs, anti-microbial and wound healing agents. More specifically, for the treatment of fish infections, examples of preferred active ingredients are natural or synthetic plant extracts (Sweet Birch, pine, coriander, and clove oils).
An overdosage of glimepiride, as with other sulfonylureas, can produce severe hypoglycemia. Mild episodes of hypoglycemia can be treated with oral glucose. Severe hypoglycemic reactions constitute medical emergencies requiring immediate treatment. Severe hypoglycemia with coma, seizure, or neurological impairment can be treated with glucagon or intravenous glucose. Continued observation and additional carbohydrate intake may be necessary because hypoglycemia may recur after apparent clinical recovery [see Warnings and Precautions (5.1)].

Please review the manufacturer's complete drug information available from the FDA at www.fda.gov   
Permanent Link: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4419ca50-539c-47e8-ab00-dbb45c7c1814
The invention relates to collagen film made from amnion, which is named as collagen biological fabric. The collagen biological fabric of the invention is provided with the structural integrity of natural untreated amnion, namely natural tertiary and quaternary structures. The invention provides a method that the amnion is decellularized and the collagen biological fabric is prepared from placenta membrane, preferably prepared from human placenta membrane with chorionic membrane and amnion. In a preferred implementation proposal, the amnion is completely decellularized. The collagen biological fabric of the invention is widely applied in the internal medicine and surgery field, including, for example, blood vessel repair, blood vessel construction and replacement, tendon and ligament replacement, wound dressing, surgical implant, ophthalmology purpose and suturation and so on. The biological fabric has the advantages of physical properties, for example, the biological mechanical strength, the flexibility, the suturation property and low immunogenicity, in particular when the biological fabric stems from human placenta.